TY - JOUR
T1 - Zidovudine- versus Tenofovir-Based Antiretroviral Therapy for the Initial Treatment of HIV Infection in the Ethnic Minority Region of Liangshan Prefecture, Sichuan Province, China
AU - Cheung, Cedric P.
AU - Lai, Wen Hong
AU - Shuter, Jonathan
N1 - Publisher Copyright:
© SAGE Publications.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background: Tenofovir (TDF)-based highly active antiretroviral therapy (HAART), as recommended by the World Health Organization guidelines for HIV-naive patients, has been limited in resource-constrained settings. The aim of this study was to evaluate the effectiveness of zidovudine-(ZDV) versus TDF-based HAART in the Yi minority region of Sichuan Province, China at a single HIV treatment center. Methods: The primary end point was the attainment of an HIV viral load <50 copies/mL. Secondary end points included change in CD4 level, adverse reactions, mortality, and sustained virologic suppression. Results: Of the 361 total participants, recipients of TDF-based HAART were more likely to achieve viral load <50 copies/mL (60% versus 46%, odds ratio [OR] = 1.7, P =.016) as well as sustained virologic suppression (61% versus 28%, OR = 3.4, P =.001). Tenofovir (adjusted odds ratio [ORadj] = 1.71, P =.025) and female sex (ORadj = 1.93, P =.003) were identified as independent predictors of achieving HIV viral load <50 copies/mL in the multivariate logistic regression analysis. Conclusion: Among Chinese Yi minority HIV-infected participants, TDF-based HAART was superior to ZDV-based HAART for initial treatment of HIV infection, suggesting TDF-based HAART should be the regimen of choice in China.
AB - Background: Tenofovir (TDF)-based highly active antiretroviral therapy (HAART), as recommended by the World Health Organization guidelines for HIV-naive patients, has been limited in resource-constrained settings. The aim of this study was to evaluate the effectiveness of zidovudine-(ZDV) versus TDF-based HAART in the Yi minority region of Sichuan Province, China at a single HIV treatment center. Methods: The primary end point was the attainment of an HIV viral load <50 copies/mL. Secondary end points included change in CD4 level, adverse reactions, mortality, and sustained virologic suppression. Results: Of the 361 total participants, recipients of TDF-based HAART were more likely to achieve viral load <50 copies/mL (60% versus 46%, odds ratio [OR] = 1.7, P =.016) as well as sustained virologic suppression (61% versus 28%, OR = 3.4, P =.001). Tenofovir (adjusted odds ratio [ORadj] = 1.71, P =.025) and female sex (ORadj = 1.93, P =.003) were identified as independent predictors of achieving HIV viral load <50 copies/mL in the multivariate logistic regression analysis. Conclusion: Among Chinese Yi minority HIV-infected participants, TDF-based HAART was superior to ZDV-based HAART for initial treatment of HIV infection, suggesting TDF-based HAART should be the regimen of choice in China.
KW - HAART
KW - HIV
KW - HIV viral load
KW - tenofovir
KW - zidovudine
UR - http://www.scopus.com/inward/record.url?scp=85016094199&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016094199&partnerID=8YFLogxK
U2 - 10.1177/2325957416686190
DO - 10.1177/2325957416686190
M3 - Article
C2 - 28043197
AN - SCOPUS:85016094199
SN - 2325-9574
VL - 16
SP - 189
EP - 193
JO - Journal of the International Association of Providers of AIDS Care
JF - Journal of the International Association of Providers of AIDS Care
IS - 2
ER -